Values First Advisors Inc. Sells 2,111 Shares of Simulations Plus, Inc. (NASDAQ:SLP)

Values First Advisors Inc. trimmed its holdings in Simulations Plus, Inc. (NASDAQ:SLP) by 5.3% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 37,977 shares of the technology company’s stock after selling 2,111 shares during the period. Values First Advisors Inc.’s holdings in Simulations Plus were worth $1,059,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of SLP. The Manufacturers Life Insurance Company boosted its holdings in shares of Simulations Plus by 7.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 6,391 shares of the technology company’s stock valued at $311,000 after acquiring an additional 456 shares during the last quarter. nVerses Capital LLC lifted its position in Simulations Plus by 1,100.0% during the third quarter. nVerses Capital LLC now owns 1,200 shares of the technology company’s stock valued at $38,000 after purchasing an additional 1,100 shares during the period. Trust Point Inc. boosted its holdings in Simulations Plus by 27.5% in the third quarter. Trust Point Inc. now owns 11,994 shares of the technology company’s stock worth $384,000 after purchasing an additional 2,589 shares during the last quarter. Tributary Capital Management LLC grew its position in Simulations Plus by 54.7% in the 3rd quarter. Tributary Capital Management LLC now owns 325,567 shares of the technology company’s stock worth $10,425,000 after purchasing an additional 115,122 shares during the period. Finally, Semanteon Capital Management LP purchased a new stake in Simulations Plus during the 3rd quarter valued at $358,000. Hedge funds and other institutional investors own 78.08% of the company’s stock.

Simulations Plus Stock Down 2.1 %

NASDAQ SLP opened at $36.05 on Wednesday. The stock’s 50-day moving average price is $30.91 and its 200-day moving average price is $32.32. The company has a market capitalization of $724.24 million, a P/E ratio of 90.13 and a beta of 0.83. Simulations Plus, Inc. has a 52 week low of $24.00 and a 52 week high of $51.22.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the company. William Blair restated an “outperform” rating on shares of Simulations Plus in a research note on Wednesday, January 8th. Stephens initiated coverage on Simulations Plus in a report on Friday, November 15th. They issued an “overweight” rating and a $39.00 target price on the stock. BTIG Research cut their price target on Simulations Plus from $60.00 to $50.00 and set a “buy” rating for the company in a research note on Thursday, October 24th. KeyCorp increased their price objective on shares of Simulations Plus from $35.00 to $37.00 and gave the stock an “overweight” rating in a research note on Friday, January 24th. Finally, StockNews.com lowered shares of Simulations Plus from a “hold” rating to a “sell” rating in a research report on Monday, November 4th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $49.40.

Insiders Place Their Bets

In other Simulations Plus news, Director Walter S. Woltosz sold 20,000 shares of the company’s stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $33.91, for a total value of $678,200.00. Following the completion of the transaction, the director now directly owns 3,402,584 shares in the company, valued at $115,381,623.44. This represents a 0.58 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 19.40% of the stock is owned by company insiders.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.